Herd management practices associated with bovine leukemia virus incidence rate in Michigan dairy farms.

The objective of this study was to identify associations between herd management practices and the incidence rate of bovine leukemia virus (BLV) infections in Michigan dairy herds. Previous management risk factor studies were of antibody prevalence rather than the rate of recent infections. Milk samples were collected from cohorts of cows on 112 Michigan dairy herds and tested for BLV using an antibody capture ELISA (n = 3849 cows). Cows were subsequently followed for an average of 21 months. Cows negative for anti-BLV antibodies and still present in their respective herds were retested by the same antibody capture ELISA to estimate within-herd incidence rates. The overall crude incidence rate was 1.46 infections per 100 cow-months at risk for the 1314 retested cows in 107 herds. The average within-herd incidence rate was 2.28 infections per 100 cow-months (range: 0 to 9.76 infections per 100 cow-months). A negative binomial regression model was used to identify herd management practices associated with the within-herd incidence rate. Results of the final multivariable model identified higher herd prevalence, milking frequency, needle reuse, as well as housing post-parturient cows separately, to be associated with increased incidence rate. Utilization of sand bedding for the lactating herd was found to be associated with decreased incidence rates. Results of this study suggest potential routes of BLV transmission which should be further investigated as disease control targets in ongoing control programs.

Economic evaluation of 4 bovine leukemia virus control strategies for Alberta dairy farms.

Bovine leukemia virus (BLV) is a production-limiting disease common in North American dairy herds. To make evidence-based recommendations to Canadian dairy producers and their consultants regarding cost and financial benefits of BLV on-farm control, an economic model that takes the supply-managed milk quota system into account is necessary. Alberta-specific input variables were used for the presented analysis. A decision tree model program was used to evaluate economic aspects of decreasing a 40% BLV within-herd prevalence on dairy farms by implementing various control strategies over 10 yr. Investigated strategies were (1) all management strategies, including 3 options for colostrum management; (2) some management strategies; (3) test and cull; and (4) test and segregate. Each of these strategies was compared with a no control on-farm approach. The prevalence for this no-control approach was assumed to stay constant over time. Each control strategy incurred specific yearly cost and yielded yearly decreases in prevalence, thereby affecting yearly partial net revenue. Infection with BLV was assumed to decrease milk production, decrease cow longevity, and increase condemnation of carcasses at slaughter from cattle with enzootic bovine leukosis, thereby decreasing net revenue. Cows infected with BLV generated a yearly mean partial net revenue of Can$7,641, whereas noninfected cows generated Can$8,276. Mean cost for the control strategies ranged from Can$193 to Can$847 per animal over 10 yr in a 146-animal herd. Net benefits of controlling BLV on farm, as compared with not controlling BLV, per cow in a 146-animal herd over a 10-yr period for each strategy was: Can$1,315 for all management strategies (freezer); Can$1,243 for all management strategies (pasteurizer); Can$785 for all management strategies (powdered colostrum); Can$1,028 for some management strategies; Can$1,592 for test and cull; and Can$1,594 for test and segregate. Consequently, on-farm BLV control was financially beneficial. Even though negative net benefits were possible and expected for some iterations, our sensitivity analysis highlighted the overall robustness of our model. In summary, this model provided evidence that Canadian dairy farmers should be encouraged to control BLV on their farm.

Using scenario tree modelling for targeted herd sampling to substantiate freedom from disease.

BACKGROUND: In order to optimise the cost-effectiveness of active surveillance to substantiate freedom from disease, a new approach using targeted sampling of farms was developed and applied on the example of infectious bovine rhinotracheitis (IBR) and enzootic bovine leucosis (EBL) in Switzerland. Relevant risk factors (RF) for the introduction of IBR and EBL into Swiss cattle farms were identified and their relative risks defined based on literature review and expert opinions. A quantitative model based on the scenario tree method was subsequently used to calculate the required sample size of a targeted sampling approach (TS) for a given sensitivity. We compared the sample size with that of a stratified random sample (sRS) with regard to efficiency. RESULTS: The required sample sizes to substantiate disease freedom were 1,241 farms for IBR and 1,750 farms for EBL to detect 0.2% herd prevalence with 99% sensitivity. Using conventional sRS, the required sample sizes were 2,259 farms for IBR and 2,243 for EBL. Considering the additional administrative expenses required for the planning of TS, the risk-based approach was still more cost-effective than a sRS (40% reduction on the full survey costs for IBR and 8% for EBL) due to the considerable reduction in sample size. CONCLUSIONS: As the model depends on RF selected through literature review and was parameterised with values estimated by experts, it is subject to some degree of uncertainty. Nevertheless, this approach provides the veterinary authorities with a promising tool for future cost-effective sampling designs.

Association between bovine-leukosis virus seroprevalence and herd-level productivity on US dairy farms.

Bovine-leukosis virus (BLV; also termed 'bovine-leukemia virus') is a retrovirus that primarily affects lymphoid tissue of dairy and beef cattle. Our objective was to investigate the association between BLV infection and annual value of production (AVP) on dairy herds within the United States, as part of the USDA National Animal Health Monitoring System's 1996 dairy study. 1006 herds (in 20 states) with at least 30 dairy cows were interviewed during 1996. The agar-gel immunodiffusion test was used to detect serum antibodies to BLV. 10-40 cows from each herd were tested and each tested cow was classified as negative or positive based on results of a single test. A multivariable regression model was used with the 976 herds with complete data for analysis. When compared to herds with no test-positive cows, herds with test-positive cows produced 218 kg per cow (i.e. 3%) less milk. The average reduction in AVP was $59 per cow for test-positive herds relative to test-negative herds. For the dairy industry as a whole, BLV seropositivity was associated with loss to producers of $285 million and $240 million for consumers. Most of this $525 million industry loss was due to reduced milk production in test-positive herds.

Direct production losses and treatment costs from bovine viral diarrhoea virus, bovine leukosis virus, Mycobacterium avium subspecies paratuberculosis, and Neospora caninum.

Our purpose was to determine direct production losses (milk loss, premature voluntary culling and reduced slaughter value, mortaliy loss, and abortion and reproductive loss) and treatmetn costs (veterinary services, medication cost, and extra farm labour cost) due to four infectious diseases in the maritime provinces of Canada: bovine viral diarrhoea (BVD), enzootic bovine leukosis (EBL), Johne's Disease (JD), and neosporosis. We used a partial-budget model, and incorporated risk and sensitivity analyses to identify the effects of uncertainty on costs. Total annual costs for an average, infected, 50 cow herd were: JD$ 2472; BVD$ 2421; neosporosis $ 2304; EBL$ 806. The stochastic nature of the proportion of infected herds and prevalence of infection within a herd were used to estimate probability distributions for these ex post costs. For all diseases, these distributions were right skewed. A sensitivity analysis showed the largest effect on costs was due to milk yield effects. For example, changing milk production loss from 0 to 5% for BVD increased the costs for the disease by 266%.